CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

NCT05442515 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

126

Enrollment

NIH

Sponsor class

Conditions

B-NHL
B-Non Hodgkin Lymphoma
Acute Lymphocytic Leukemia
Acute Lymphoblastic Leukemia
B-precursor ALL
B-All
Lymphoma, Non-Hodgkin
Leukemia, Lymphocytic, B Cell
B-Cell Lymphoma
B-Cell Leukemia
Acute Lymphoid Leukemia

Interventions

BIOLOGICAL: CD19/CD22-CAR-transduced T cells
DRUG: cyclophosphamide
DRUG: fludarabine

Sponsor

National Cancer Institute (NCI)